Pharmacogenetics and geographical ancestry: implications for drug development and global health
- 1 March 2005
- journal article
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 6 (3) , 241-246
- https://doi.org/10.1038/nrg1559
Abstract
Understanding and harnessing genomic variation will contribute significantly to improving the health of people in developing countries. We need to explore the nexus between pharmacogenetics, genotyping projects in developing countries, and the evolution of the pharmaceutical industry in both the developed and developing worlds. Here, we argue that, for the foreseeable future, we should focus not on boutique 'personalized' medicine, but on carefully defined differences between populations and ethical ways of using emerging genomics knowledge to develop drugs and improve health.Keywords
This publication has 47 references indexed in Scilit:
- Strengthening the Role of Genomics in Global HealthPLoS Medicine, 2004
- Conclusions: promoting biotechnology innovation in developing countriesNature Biotechnology, 2004
- Will tomorrow's medicines work for everyone?Nature Genetics, 2004
- Detection of large-scale variation in the human genomeNature Genetics, 2004
- The International HapMap ProjectNature, 2003
- Race and MedicineScience, 2003
- A vision for the future of genomics researchNature, 2003
- Genetic Structure of Human PopulationsScience, 2002
- Drug development for neglected diseases: a deficient market and a public-health policy failureThe Lancet, 2002
- Inhibitors of the Nonmevalonate Pathway of Isoprenoid Biosynthesis as Antimalarial DrugsScience, 1999